Are we entering the era of biologics for COPD?
In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma.
Approaches like bronchodilator inhalers focus on treating both asthma and chronic obstructive pulmonary disease (COPD). The same, however, is not true for therapeutic biologics. While th